부산대학교 도서관

Background: We explored inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE) coexistence using a global dataset. Investigating their epidemiology, risks, and impact, we aimed to enhance the understanding of concurrent diagnoses and patient outcomes. Methods: A retrospective population-based cohort study was conducted using deidentified patient data from the TriNetX database (2011–2022). We estimated the incidence and prevalence of EoE in patients with IBD, including both Crohn's disease (CD) and ulcerative colitis (UC), and vice versa. Risks of select immune-mediated conditions and disease complications were compared among patients with EoE, IBD, or concurrent diagnoses. Results: Our results included 174,755 patients with CD; 150,774 patients with UC; and 44,714 patients with EoE. The risk of EoE was significantly higher among patients with CD (prevalence ratio [PR] 11.2) or UC (PR 8.7) compared with individuals without IBD. The risk of IBD was higher in patients with EoE (CD: PR 11.6; UC: PR 9.1) versus those without EoE. A propensity-matched analysis of IBD patients revealed that, when comparing patients with and without EoE, the relative risk of immune-mediated comorbidities was significantly greater for celiac disease, IBD-related inflammatory conditions, eczema and asthma (CD: n = 1896; UC: n = 1231; p < 0.001). Patients with a concurrent diagnosis of EoE and IBD had a higher composite risk of IBD-related complications (CD: adjusted HR (aHR) 1.14, p < 0.005; UC: aHR 1.17, p < 0.01) and lower risk of food bolus impaction (aHR 0.445, p = 0.0011). Conclusion: Simultaneous EoE and IBD increased IBD-related complications risk, needing more treatment (glucocorticoids, biologic therapy, abdominal surgery), while reducing EoE-related issues like food bolus impaction. Key Message: • What is already known?: There is a significantly higher prevalence of EoE among IBD patients and vice versa, but existing research has yielded inconsistent findings regarding the development of EoE-related or IBD-related complications among patients with a co-diagnosis of both conditions. • What is new here?: This study represents the first globally-representative population-based study with inclusion of patients enrolled in government-funded insurance plans that examines the overlapping features of EoE and IBD. • How can this study help patient care?: This research underscores the need for vigilant monitoring and a meticulous approach to potential complications in patients diagnosed with both conditions as treatment methodologies continue to evolve particularly in the realm of biologic therapies. [ABSTRACT FROM AUTHOR]